Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients.

MLA

Martino, Massimo, et al. “Administration of Recombinant Human Erythropoietin Alpha before Autologous Stem Cell Transplantation Reduces Transfusion Requirement in Multiple Myeloma Patients.” Supportive Care in Cancer, vol. 13, no. 3, Mar. 2005, pp. 182–87. EBSCOhost, https://doi.org/10.1007/s00520-004-0686-2.

APA

Martino, M., Oliva, E., Console, G., Stelitano, C., Fujo, M., Messina, G., Irrera, G., Pucci, G., Mandaglio, R., Callea, V., Nobile, F., Iacopino, P., & Morabito, F. (2005). Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients. Supportive Care in Cancer, 13(3), 182–187. https://doi.org/10.1007/s00520-004-0686-2

Chicago

Martino, Massimo, Esther Oliva, Giuseppe Console, Caterina Stelitano, Mohamed Fujo, Giuseppe Messina, Giuseppe Irrera, et al. 2005. “Administration of Recombinant Human Erythropoietin Alpha before Autologous Stem Cell Transplantation Reduces Transfusion Requirement in Multiple Myeloma Patients.” Supportive Care in Cancer 13 (3): 182–87. doi:10.1007/s00520-004-0686-2.